Volume 16, Issue 3 , Pages 311-319, March 2010
Chemokine Receptor CCR5 Mediates AlloImmune Responses in Graft-versus-Host Disease
Article Outline
Allogeneic bone marrow transplantation (BMT) is an effective therapy for hematologic malignancies. However graft-versus-host disease (GVHD) is a major limiting factor for a successful patient outcome. GVHD is a result of alloimmune responses of donor T lymphocytes attacking the recipient's cells and tissues. Chemokine receptor CCR5 plays a role in solid organ allograft rejection and mediates murine GVHD pathogenesis. Herein, we report that infiltrating lymphocytes in the skin of human acute GVHD (aGVHD) samples are predominantly CCR5+ T cells. In addition, we characterized the features of the CCR5 expression on alloreactive T lymphocytes. We found that the CCR5+ population exhibits the characteristics of the activated effector T cell phenotype. CCR5 expression is upregulated upon allogenic stimulation, and CCR5+ cells are proliferating with coexpression of T cell activation markers. Furthermore, the activated T cells producing inflammatory cytokine tumor necrosis factor (TNF)α, interleukin (IL)-2, or interferon (IFN)-γ, are positive for CCR5. Thus, CCR5 is a marker for GVHD effector cells and CCR5+ T cells are active participants in the pathogenesis of human aGVHD.
Key Words: CCR5, GVHD, Chemokine, CD4, CD8
Introduction
Graft-versus-host disease (GVHD) is the major cause of morbidity and mortality in allogeneic hematopoietic cell transplantation (HCT) recipients because of alloimmune responses [1]. The disease is characterized primarily by targeted epithelial cell injury in skin, intestines, and liver 2, 3, 4. The development of GVHD is thought to involve 3 phases: T cell activation, followed by proliferation and differentiation of allogeneic T cells into activated effector cells, and finally specific tissue damage 5, 6. The main effector cells in GVHD are T lymphocytes, although their precise phenotype remains elusive. Current evidence suggests that GVHD represents a systemic T helper (Th)1 type response: this characterization includes a CD4 response of Th1 type, resulting in CD8 cytotoxic T lymphocyte (CTL) generation and an inflammatory cytokine cascade [6].
Chemokines and their receptors play an important role in regulating leukocyte migration and activation [7]. Recently, the functional state of T cells has been characterized by the chemokine receptor expression pattern 7, 8, 9. In particular, chemokine receptor CCR5 is a marker for effector T cells. CCR5 is a coreceptor for HIV entry and has been studied extensively [10]. The expression of CCR5 is very low on naïve T cells, but is highly upregulated on both CD4+(Th1) T cells and activated antigen-specific CD8+ T cells 11, 12. The function of CCR5 and its ligands in GVHD has been primarily explored in murine models. It has been reported that CCR5+/CD8+ T cells mediate hepatic injury in mouse GVHD and blocking antibody to CCR5 reduces the damage [13]. In addition, MIP-1α, 1 of the ligands for CCR5, has also been shown to mediate mouse GVHD 14, 15. Although 2 groups demonstrated that genetic deletion of CCR5 in the donor can reduce acute GVHD (aGVHD) in mice 16, 17; others reported that CCR5−/− or MIP-1α−/− donor T cells accelerate GVHD in the liver and lung 17, 18. These data suggested that the role of CCR5 in alloimmmune responses is complicated, and probably regulated in strain-, target organ-, or pretransplant conditioning-dependent fashion in murine GVHD models [17]. In addition to T cells, other cell types such as dendritic cells (DCs) and B cells are involved in the pathogenesis of GVHD 19, 20. CCR5 has been shown to express on DCs and specifically the dermal Langerhans cells 21, 22. Langerhans cells represent the specialized DCs of the epidermis, and play an important role in skin GVHD [19]. Clearly, the role of CCR5 is intricate and complicated, and the field is as of yet still unresolved regarding the role of CCR5 in human GVHD.
It has been shown that infiltration of CCR5+ T cells occurs in both the acute and chronic phases of human renal allograft rejection [23]. A large cohort of patients genetically lacking CCR5 (CCR5Δ32) demonstrated the functional importance of CCR5 in human renal allograft survival [24]. Recently, we have identified donors genetically lacking CCR5 and these donors were correlated with the outcome of patients who received major histocompatibility complex (MHC)-matched unrelated HCT [25]. We found a decreased incidence of GVHD in the absence of CCR5 on donor T cells. In this study, we report that lymphocyte infiltrates at the skin sites of human aGVHD are predominantly CCR5+ T cells, including both CD4+ and CD8+ subsets. Upon allogeneic stimulation, the majority of CCR5+ cells demonstrated characteristics of activated proliferating T cells with coexpression of activation marks and production of inflammatory cytokines.
Materials and Methods
Immunohistochemistry
Skin and lip biopsies were retrieved from the GVHD tissue repository at the Fred Hutchinson Cancer Center (FHCC) from patients transplanted between 1988 and 2000 25, 26. Formalin-fixed paraffin-embedded sections of skin and lip were examined by hematoxylin and eosin stain, and CD3, CD4, CD8, CCR5, CD1a, and CD20 immunostains performed using avidin-biotin conjugated reagents. The coexpression of CCR5 in combination with CD4 or CD8 was performed using DAKO Envision Double System (DAKO System) that can detect 2 antigens from the same species within 1 specimen. The skin biopsies were double stained with CCR5 antibody and either CD4 or CD8 antibodies (Texas-Red). The same slides were photographed by light and fluorescence microscopy for Texas-Red.
Dendritic Cell Culture
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coat preparations derived from whole blood of healthy volunteer donors (Gulf Coast Regional Blood Center, Houston, TX). The buffy coat was diluted with phosphate-buffered saline (PBS) at a 1:2 ratio and centrifuged over Histopaque-1077 (Sigma Diagnostics, St. Louis, MO) for 30 minutes. The PBMC interface was collected and analyzed for purity by flow cytometry and frozen for future use. DCs were generated from CD14-positive selected monocytes using magnetic beads (Miltenyi Biotec, Gladbach, Germany). The CD14-positive fraction was cultured in RPMI plus 50 ng/mL granulocyte macrophage colony-forming unit (GM-CSF) and 10 ng/mL interleukin (IL)-4. On day 6, 1/100 dilution of maturation cytokine factor 100× PITIP (1 μg/mL Poly [cytidylic-inosinic] acid, 1 μg/mL IL-1β, 1 μg/mL tumor necrosis factor (TNF)-α, 1.5 μg/mL IL-6, 100 μg/mL Prostaglandin E2) was added to the differentiation culture as described [27]. DCs were collected on day 9 of culture.
Mixed Lymphocyte Reaction
Frozen PBMCs from healthy volunteer donors were thawed and cultured in RPMI plus 10% fetal bovine serum (FBS) and 1% streptomycin/penicillin. After 24 hours, the cells were counted and resuspended to 1 × 106 cells/mL and labeled either responder or stimulator. This day is labeled day 0, and cells were assayed on day indicated in figure legends. The responders were mixed in a 1:1 ratio with irradiated stimulator (allogeneic) or irradiated responders (autologous) mixed lymphocyte reaction (MLR), respectively. Where indicated, the MLR was carried out using DCs; allogeneic or autologous DC MLR was performed using a DC:PBMC ratio of 1:100. Cells were collected and stained on days 3, 6, 9, and/or day 12, as indicated in figure legends.
Intracellular Cytokine Assay
The intracellular cytokine staining was carried out as previously described [28]. In brief, the MLR cultures were treated on the indicated day with Brefeldin A (final concentration of 10 μg/mL) for 5 hours at 37°C. Cells were then collected, washed, and stained for surface expression of CD4, CD8, and CCR5. Cells were washed and permeabilized using BD FACS Permeabilizing Solution 2 (BD Biosciences, San Jose, CA) for 10 minutes with occasional mild vortex. Cells were washed and stained for intracellular cytokines using fluorescent-tagged antibodies against TNFα, IL-2, and inteferon (IFN)-γ (BD Biosciences).
Results
Infiltrating T Cell Lymphocytes in the Skin of Human aGVHD Are Predominantly CCR5+ Cells
Based on our recent report, patients who received bone marrow (BM) from CCR5Δ32 homozygous donors had lower risk of skin GVHD than the control group, with an odds ratio of 0.19 and 95% confidence interval of 0.05-0.80 and the difference is statistically significant (P = .02) [25]. This implicated CCR5 expression might mediate the invasion of lymphocytes into the skin, liver, and gut, which is the characteristic feature of GVHD [6]. We therefore examined the degree of expression of CCR5 in the lymphocytes in the skin of human aGVHD. We screened our GVHD tissue repository of allograft recipients, to select 10 samples from skin and lip that showed histologic features of aGVHD (epithelial apoptosis associated with lymphocyte infiltration) and had the most abundant number of lymphocytes. Samples were stained with CCR5, CD3, CD4, and CD8 antibodies.
As shown in Figure 1A, a representative example of GVHD skin (top panel) and lip (lower panel), lymphocytes were found near the dermal and epidermal junctions, and were concentrated in the basal layer. Adjacent sections that were stained with CCR5 antibody or CD3 antibody showed a similar pattern. Figure 1B is a representative example of the lip biopsy of a GVHD patient: the salivary gland was damaged by lymphocytes, which resulted in the dry mouth symptoms often seen in GVHD patients. The pattern of CCR5 antibody staining in these lip biopsies is similar to that of CD3 staining, suggesting that the gland-infiltrating lymphocytes were CCR5+ T cells. To determine whether the CCR5+ T cells were CD4+ versus CD8+, we examined the coexpression of CCR5 in combination with CD4 or CD8, using the DAKO Envision Double System that can detect 2 antigens from the same species within 1 specimen. As shown in Figure 2, the majority of infiltrating cells were double stained with either CD4 or CD8 and CCR5. Thus, CCR5 expression is present on the majority of both CD4+ and CD8+ T cells involved in skin GVHD.
Figure 1
Infiltrating T cell lymphocytes in human aGVHD tissues are predominantly CCR5+. (A) Skin and lip biopsies of GVHD patients. Three adjacent sections of skin (top panel) and lip (lower panel) biopsies of a representative GVHD patient were stained with H&E, CCR5 antibody, or CD3 antibody. CCR5+ and CD3+ lymphocyte infiltrates were found in both the dermal and epidermal layers. (B) Lip biopsy of a representative GVHD patient with damaged salivary gland. Right and left panels are adjacent sections stained with CCR5 or CD3 antibodies. In each panel, the right side is an enlarged picture of the area with the arrow. CCR5+ and CD3+ lymphocyte infiltrates were found in the damaged area of salivary gland.
Figure 2
Infiltrating CCR5+ T cell lymphocytes in the skin of aGVHD are both CD4+ and CD8+ T cells. The skin biopsies of a representative GVHD patient were double stained with CCR5 antibody and either CD4 antibody (top panel) or CD8 antibody (bottom panel). On the right side, CCR5+ cells are brown, and both CD4+ and CD8+ cells are Texas-Red. The same slides were photographed by light (right panel) and fluorescence microscopy (left panel) for Texas-Red.
In addition, we examined all 10 skin and lip biopsies for Langerhans DC marker CD1a and B cell marker CD20. No CD20+ B cells were noted (data not shown) and CD1a+ epidermal Langerhans cells were abundant in 5 samples. The samples with heavy Langerhans cell infiltrates were retrieved for CCR5 staining. Representative sections are shown in Figure 3. In the top panel, the skin biopsy with extensive epidermal damage has CCR5 expression on the vast majority of T cell infiltrates in the superficial dermis (arrows) and epidermis, with increased CD1a+ Langerhans DCs at sites of lymphocytic infiltration. The foci of epidermal damage has high-level CCR5 expression on T cells, but weak to minimal CCR5 staining on Langerhans DCs (middle panel). In the bottom panel, lip biopsy from a case with minimal lymphoid infiltrate or epithelial damage shows no detectable CCR5 expression on CD1a+ Langerhans DCs. Thus, strong CCR5 expression is present on T cells but not DCs in the skin of aGVHD.
Figure 3
Strong CCR5 expression on T cells but not dendritic cells in aGVHD tissues. Immunohistochemistry was performed on paraffin sections for CCR5 (left panel) and Langerhans DC marker CD1a (right panel). Top panel: skin biopsy with CCR5+ T cells in the superficial dermis (arrows) and epidermis in addition to CD1a+ Langerhans DCs at sites of lymphocytic infiltration. Middle panel: foci of epidermal damage with high-level CCR5 expression in T cells (arrow) but weak CCR5 staining in CD1a+ Langerhans DCs. Bottom panel: lip biopsy from a case with minimal epithelial damage and no detectable CCR5 expression in CD1a+ Langerhans DCs.
CCR5 Is Expressed on Activated T Cells and Upregulated on Proliferating T Lymphocytes following Allogeneic Activation
To dissect the human alloimmune responses mediated by CCR5+ T cells, we used MLR with allogeneic DCs mixed with responder PBMCs for lymphocyte activation and proliferation. We found that the expression level of CCR5 on both the CD4+ and CD8+ T cells increased from day 3 and peaked at days 6-9 after allogeneic MLR (data not shown). We further examined the characteristics of the CCR5+ T cells after allogeneic MLR. As shown in Figure 4, the majority of CCR5+ were CD45RA−/CD45RO+ with decreased expression of CD62L and CD69, representing the activated T cell phenotype. Furthermore, we examined whether the CCR5+ population was actively proliferating. CFSE (carboxy fluorescein succinimidyl ester)-labeled responder cells were plated with stimulator cells and cell proliferation was measured by CFSE intensity with FACS. As shown in Figure 5, the proliferating CD4+ and CD8+ T cells with low CFSE staining were positive for CCR5. Thus, the expression of CCR5 is greatly restricted to the proliferating T lymphocytes. In contrast, both CCR7 and CXCR3 do not appear to have the same restriction to proliferating cells as CCR5.
Figure 4
CCR5 is coexpressed with T cell activation markers. Mixed lymphocyte culture (MLR) were used to activate PBMC from normal donors with allogenic DCs mixed with responder PBMCs (DC-MLR) at a DC:PBMC ratio of 1:100. The cells were collected 7 days after stimulation and stained with antibodies CD4, CD8, CCR5, and a panel of activation markers including CD45RA, CD45RO, CD62L, and CD69. The representative dot plots of CD4 (upper panel) and CD8 (lower panel) T cells demonstrated the coexpression of CCR5 and activation marks. Data were representative of experiments from 3 independent samples. Cells were collected on a FACscaliber Flow Cytometer and data was analyzed by Cell Quest software (Becton Dickinson).
Figure 5
CCR5 is upregulated on proliferating T cell lymphocytes following allogeneic activation. Responder PBMCs were incubated in CFSE for 10 minutes and then washed with PBS for coculture with allogenic DCs. Cells were collected 9 days after stimulation and stained with CD4 and CD8 antibodies. The gated lymphoblast population of CD4+ or CD8+ T cells were analyzed separately for CCR5, CCR7, and CXCR3 expression. Data shown here are representative of 3 independent samples.
CCR5+ T Cells Produce Cytokine TNFα, IL-2, and IFN-γ
The mechanism of GVHD has been described as a “cytokine storm” because of the central role of cytokines in mediating tissue injury and inflammation characteristic of GVHD pathology [6]. Therefore, we assessed whether cells producing the cytokine TNFα, IL-2, and IFN-γ were positive for CCR5. Cells were treated with brefeldin A 7 days post-MLR and were stained for CD4, CD8, and CCR5. The expression of cytokines was measured by intracellular staining with antibodies against TNFα, IL-2, or IFN-γ. As shown in Figure 6 (top panel), the CD4+ (A) or CD8+ (B) T cells producing intracellular TNFα were gated and analyzed for CCR5 expression. The majority of TNFα producing cells were positive for CCR5, with about 80.5% for CD4+ and 79.9% for CD8+ T cells, respectively. We found a similar pattern of CCR5 expression in IL-2 producing cells (Figure 6, middle panel). The majority of IFN-γ producing cells (74.5%) were positive for CCR5 in the CD4+ T cell population, whereas only about 56.9% were positive for CCR5 in the CD8+ T cell population (Figure 6, bottom panel). In conclusion, CD4+ T cells that produce cytokine TNFα, IL-2, or IFN-γ, were expressing CCR5. However, CCR5 expression was only detected on TNFα or IL-2 producing CD8+ T cells and about half of IFN-γ producing CD8+ T cells were negative for CCR5 expression.
Figure 6
CCR5+ T lymphocytes and intracellular cytokine production of TNFα, IL-2, and IFN-γ. Allogenic DCs mixed with responder PBMCs (DC-MLR) at a DC:PBMC ratio of 1:100. The MLR cultures were treated with brefeldin-A on day 7 for 5 hours. The cells were harvested and stained with CD4, CD8, CCR5, and intracellular cytokines TNFα (top panel), IL-2 (middle panel), and IFN-γ (bottom panel). The left panel of A (CD4) and B (CD8) were the representative dot-plots of intracellular cytokine production and the gated cells were positive for the cytokine using autologous MLR sample as the reference. The right panel of A and B was the CCR5 expression of the gated cells from the respective upper panel, and the quadrant gates were decided based on isotype control. Results were representative of 4 independent samples.
Discussion
In the current study, we investigated the role of chemokine receptor CCR5 in skin GVHD and alloimmune responses. We demonstrated that CCR5 expression is present on both CD4+ and CD8+ T cell infiltrates in the skin biopsies of human aGVHD. CCR5 is upregulated upon allostimulation and expressed on activated T cells. In addition, the expression of CCR5 is restricted to the proliferating T lymphocytes. Furthermore, we found that activated T cells producing cytokine TNFα, IL-2, or IFN-γ are positive for CCR5. Together, our data indicated that CCR5 expression on T cells mediates allo-immune responses in GVHD.
CCR5 is considered 1 of the “inflammatory” chemokine receptors regulated by proinflammatory stimuli to orchestrate immune responses, in comparison with the “homeostatic “ group, which are important in immune surveillance such as CCR7. Inflammatory chemokine receptors are upregulated during tissue damage or inflammation, and involved in T cell polarization 29, 30, 31. Gene expression profiles have shown that CCR5 was upregulated during aGVHD in human 32, 33. Our data further demonstrated that CCR5 expression is on activated and proliferating T cells upon allogeneic stimulation. In contrast, CCR7 was found within both proliferating and nonproliferating T cells, and there was no significant increase in the expression of CCR7. Interestingly, CXCR3, another inflammatory chemokine receptor, does not show the same restriction to proliferating cells as CCR5. Although almost all proliferating T cells were positive for CXCR3, there was a high percentage of nonproliferating T cells expressing this chemokine receptor. Thus, the data suggests a critical role of CCR5 expression in alloimmune responses and GVHD.
We and others have demonstrated that the protective effect of the CCR5 deletion mutation in GVHD 25, 34. In a small cohort study, we found that in the absence of CCR5 on donor cells, there is a decreased incidence of GVHD and increased relapse rate in recipients with HLA-matched unrelated marrow donors [25]. In particular, there is a significant reduction of skin GVHD. We further examined the skin and lip biopsies from aGVHD patients for CCR5 expression in situ, and found the majority of infiltrating T cells were positive for CCR5. Altogether, these data confirms that CCR5 expression plays an important role in mediating human GVHD.
CCR5 is highly upregulated on both CD4+(Th1) T cells and activated antigen-specific CD8+ T cells 11, 12. Using an intracellular cytokine assay, we found that activated CD4+ T cells that produce inflammatory cytokine TNFα, IL-2, or IFN-γ, were positive for CCR5. In addition, the TNFα and IL-2-producing CD8+ T cells also expressed CCR5. This observation supported the notion that CCR5 is a marker for effector T cells that actively participate in the “cytokine storm” of GVHD [6].
Chemokines and their receptors are important in many human diseases, including HIV, autoimmune disease, inflammatory disease, and organ graft rejection [35]. Currently, small molecule antagonists and humanized monoclonal antibodies (mAbs) targeting chemokine receptors are developed by industry and tested in preclinical models as well as in phase I trials 36, 37, 38, 39. Our data demonstrated that CCR5+ T cells are important in mediating GVHD in humans. The results will provide rationale to develop novel treatment for GVHD.
Acknowledgments
Financial disclosure: This work was supported by grants from the Wendy Will Case Cancer Fund (to Q.M.), and CA18029, CA15704, and CA78902 from the National Institutes of Health (to R.F.S.).
References
- . Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385–389
- . The Pathology of Organ Transplantation. London: Butterworth Publishers, Inc.; 1990;229-260
- . The pathophysiology of graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ editor. Hematopoietic Cell Transplantation. Boston, MA: Blackwell Scientific Publications; 1994;p. 305–315
- . Does graft-versus-host disease attack epithelial stem cells?. Mol Med Today. 1996;2:114–119
- . Graft-versus-host disease as a Th1-type process: regulation by donor cells of Th2 cytokine phenotype. In: Ferrara JLM, Deeg HJ, Burakoff SJ editor. Graft-vs.-Host Disease. New York: Marcel Dekker Inc.; 1997;p. 479–500
- . Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors. J Hematother Stem Cell Res. 2000;9:299–306
- . Chemokines as regulators of T cell differentiation. Nat Immunol. 2001;2:102–107
- . Lymphocyte traffic control by chemokines. Nat Immunol. 2001;2:123–128
- . Chemokines and the tissue-specific migration of lymphocytes. Immunity. 2002;16:1–4
- . The role of chemokines in human immunodeficiency virus infection. Immunol Rev. 2000;177:79–87
- . Differentiation of human CD8+ T cells from a memory to memory/effector phenotype. J Immunol. 2002;168:5538–5550
- . Functional expression of the chemokine receptor CCR5 on virus epitope-specific memory and effector CD8+ T cells. J Immunol. 2002;168:2225–2232
- Related active participation of CCR5+CD8+ T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest. 1999;104:49–57
- . Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier. Blood. 1999;93:43–50
- T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8+ T cells to the liver, lung, and spleen during graft-versus-host disease. Blood. 2000;96:2973–2980
- Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol. 2003;4:154–160
- Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J Immunol. 2004;173:845–854
- . Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 alpha (CCL3) after allogeneic BMT in mice. Blood. 2003;101:3714–3721
- Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med. 2004;5:510–517
- . The role of B Cells in the pathogenesis of graft-versus-host disease. Blood. 2009;2009 Sep 11 [Epub ahead of print]
- . Expression of chemokines and chemokine receptors in lesional and nonlesional upper skin of patients with atopic dermatitis. J Allergy Clin Immunol. 2009;124:753–760
- Transcriptional profiling of human skin-resident Langerhans cells and CD1a+ dermal dendritic cells: differential activation states suggest distinct functions. J Leukoc Biol. 2008;84:143–151
- Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis. 2001;37:518–531
- CC chemokine receptor 5 and renal-transplant survival. Lancet. 2001;357:1758–1761
- . CCR5 expression on cells from HLA-matched unrelated marrow donors and graft-versus-host disease. Biol Blood Marrow Transplant. 2009;doi: 10.1016/j.bbmt.2009.05.003
- Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962–968
- AML-loaded DC generate Th1-type cellular immune responses in vitro. Cytotherapy. 2006;8:95–104
- Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood. 2004;104:3429–3436
- . Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–127
- . Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med. 1998;187:875–883
- . T cell effector subsets: extending the Th1/Th2 paradigm. Adv Immunol. 2001;78:233–266
- . Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:280–287
- . Gene-expression profiles of peripheral blood mononuclear cell subpopulations in acute graft-vs-host disease following cord blood transplantation. Exp Hematol. 2008;36:1760–1770
- . CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91:1628–1634
- . Chemokines and disease. Nat Immunol. 2001;2:108–115
- . Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol. 2002;2:106–115
- . New anti-HIV agents and targets. Med Res Rev. 2002;22:531–565
- . Development and evaluation of pharmacological agents targeting chemokine receptors. Methods. 2003;29:369–375
- The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies. J Clin Pharm Ther. 2009;34:147–160
Financial disclosure: See Acknowledgments on page 318.
PII: S1083-8791(09)00586-2
doi:10.1016/j.bbmt.2009.12.002
© 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Volume 16, Issue 3 , Pages 311-319, March 2010
